title: Poly (AT) deletion/insertion polymorphism of the XPC gene contributes to urinary system cancer susceptibility: a meta-analysis.
abstract: Numerous studies have investigated the association between xeroderma pigmentosum complementation group C (XPC) poly (AT) deletion/insertion (PAT -/+) polymorphism and cancer susceptibility; however, the findings are inconsistent. Therefore, we performed a meta-analysis based on 32 publications including 10,214 cases and 11,302 controls to acquire a more robust estimation of the relationship. We searched publications from MEDLINE, EMBASE and CBM which assessed the associations between XPC PAT -/+ polymorphism and cancer risk. We calculated pooled odds ratio (OR) and 95% confidence interval (CI) by using either fixed-effects or random-effects model. We found that individuals carrying the PAT +/+ genotype have significantly increased cancer risk (PAT +/+ vs.
  OR=1.18, 95% CI=1.03-1.35 and recessive model: OR=1.19, 95% CI=1.06-1.33). Further stratification analysis showed a significantly increased risk for prostate cancer (PAT +/+ vs.
  OR=2.20, 95% CI=1.39-3.48, recessive model: OR=2.07, 95% CI=1.33-3.23 and PAT + vs.
  OR=1.39, 95% CI=1.12-1.71), bladder cancer (recessive model: OR=1.33, 95% CI=1.03-1.72), Caucasian ethnicity (recessive model: OR=1.21, 95% CI=1.02-1.43), population-based studies (recessive model: OR=1.23, 95% CI=1.05-1.43) and studies with relatively large sample size (PAT +/+ vs.
  OR=1.18, 95% CI=1.04-1.35 and recessive model: OR=1.20, 95% CI=1.08-1.33). Despite some limitations, this meta-analysis established solid statistical evidence for the association between the XPC PAT +/+ genotype and cancer risk, especially for urinary system cancer, but this association warrants further validation in single large studies.
authors.affiliation: Department of Oncology, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510080, China. daiqs@163.com
authors.forename: Qiang-Sheng
authors.initials: QS
authors.lastname: Dai
authors.forename: Rui-Xi
authors.initials: RX
authors.lastname: Hua
authors.forename: Ruoxin
authors.initials: R
authors.lastname: Zhang
authors.forename: Yu-Shan
authors.initials: YS
authors.lastname: Huang
authors.forename: Zhu-Ming
authors.initials: ZM
authors.lastname: Hua
authors.forename: Cheang Tuck
authors.initials: CT
authors.lastname: Yun
authors.forename: Rui-Fang
authors.initials: RF
authors.lastname: Zeng
authors.forename: Jian-Ting
authors.initials: JT
authors.lastname: Long
mesh_terms: D016022:Case-Control Studies; D004268:DNA-Binding Proteins / Q000235:genetics*; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D006801:Humans; D054643:INDEL Mutation; D011110:Polymorphism, Genetic; D001749:Urinary Bladder Neoplasms / Q000235:genetics*
chemical_list: D004268:DNA-Binding Proteins; C086984:XPC protein, human
keywords: CBM; CI; Chinese Biomedical; DNA repair capacity; DRC; HWE; Hardy–Weinberg equilibrium; Meta-analysis; NER; OR; PAT; PAT −/+; Polymorphism; SCCNH; SNP; Susceptibility; XPC; confidence interval; nucleotide excision repair; odds ratio; poly (AT) deletion/insertion; single nucleotide polymorphism; squamous cell carcinoma of the head and neck; xeroderma pigmentosum complementation group C